Literature DB >> 28870674

Development of chronic kidney disease in patients with non-alcoholic fatty liver disease: A cohort study.

Dong Hyun Sinn1, Danbee Kang2, Hye Ryoun Jang1, Seonhye Gu3, Soo Jin Cho4, Seung Woon Paik1, Seungho Ryu5, Yoosoo Chang5, Mariana Lazo6, Eliseo Guallar7, Juhee Cho8, Geum-Youn Gwak9.   

Abstract

BACKGROUND & AIMS: Non-alcoholic fatty liver disease (NAFLD) has been associated with chronic kidney disease (CKD), but cohort studies are limited. We investigated the longitudinal association of NAFLD and its severity with the development of CKD.
METHODS: We performed a retrospective cohort study of 41,430 adult men and women (average age, 48.9y) without CKD at baseline who underwent repeated health check-up examinations from January 1, 2003, through December 31, 2013. NAFLD status was assessed by ultrasonography, and NAFLD severity was assessed by the NAFLD fibrosis score (NFS).
RESULTS: The outcome was an incident CKD, defined as an estimated glomerular filtration rate less than 60ml/min/1.73m2. During 200,790 person-years of follow-up (median follow-up of 4.15years), we identified 691 incident CKD cases. The multivariable-adjusted hazard ratio for CKD comparing participants with and without NAFLD was 1.22 (95% confidence interval [CI] 1.04-1.43). The risk of CKD increased progressively with increased NAFLD severity. The multivariable-adjusted hazard ratios for CKD comparing participants with NFS <-1.455 and those with NFS ≥-1.455 to participants without NAFLD were 1.09 (95% CI 0.91-1.32) and 1.58 (95% CI 1.30-1.92), respectively. The association was consistent across clinically relevant subgroups.
CONCLUSION: In a large cohort of adult men and women without CKD, NAFLD was associated with an increased risk of CKD development. NAFLD may adversely affect renal function and patients may need to be carefully monitored for an increased risk of CKD. LAY
SUMMARY: The presence of fatty liver is associated with the future decline of renal function. Thus, fatty liver patients need to be monitored regularly for renal function.
Copyright © 2017 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Chronic kidney disease; Cohort; Fatty liver; Liver fibrosis

Mesh:

Year:  2017        PMID: 28870674     DOI: 10.1016/j.jhep.2017.08.024

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  31 in total

Review 1.  Therapeutic implications of shared mechanisms in non-alcoholic fatty liver disease and chronic kidney disease.

Authors:  Mehmet Kanbay; Mustafa C Bulbul; Sidar Copur; Baris Afsar; Alan A Sag; Dimitrie Siriopol; Masanari Kuwabara; Silvia Badarau; Adrian Covic; Alberto Ortiz
Journal:  J Nephrol       Date:  2020-05-21       Impact factor: 3.902

Review 2.  Non-Alcoholic Fatty Liver Disease and Cardiovascular Comorbidities: Pathophysiological Links, Diagnosis, and Therapeutic Management.

Authors:  Alexandra Jichitu; Simona Bungau; Ana Maria Alexandra Stanescu; Cosmin Mihai Vesa; Mirela Marioara Toma; Cristiana Bustea; Stela Iurciuc; Marius Rus; Nicolae Bacalbasa; Camelia Cristina Diaconu
Journal:  Diagnostics (Basel)       Date:  2021-04-12

3.  Nonalcoholic fatty liver disease increases risk of incident advanced chronic kidney disease: a propensity-matched cohort study.

Authors:  Haesuk Park; Ghadeer K Dawwas; Xinyue Liu; Mindie H Nguyen
Journal:  J Intern Med       Date:  2019-08-23       Impact factor: 8.989

4.  Advanced liver fibrosis measured by transient elastography predicts chronic kidney disease development in individuals with non-alcoholic fatty liver disease.

Authors:  Chan-Young Jung; Geun Woo Ryu; Hyung Woo Kim; Sang Hoon Ahn; Seung Up Kim; Beom Seok Kim
Journal:  Diabetologia       Date:  2021-12-21       Impact factor: 10.122

Review 5.  MAFLD and CKD: An Updated Narrative Review.

Authors:  Alessandro Mantovani; Rosa Lombardi; Filippo Cattazzo; Chiara Zusi; Davide Cappelli; Andrea Dalbeni
Journal:  Int J Mol Sci       Date:  2022-06-23       Impact factor: 6.208

6.  Non-alcoholic fatty liver disease increases the risk of incident chronic kidney disease.

Authors:  Leonard Kaps; Christian Labenz; Peter R Galle; Julia Weinmann-Menke; Karel Kostev; Jörn M Schattenberg
Journal:  United European Gastroenterol J       Date:  2020-07-23       Impact factor: 4.623

Review 7.  Non-alcoholic fatty liver and chronic kidney disease: Retrospect, introspect, and prospect.

Authors:  Rajiv Heda; Masahiko Yazawa; Michelle Shi; Madhu Bhaskaran; Fuad Zain Aloor; Paul J Thuluvath; Sanjaya K Satapathy
Journal:  World J Gastroenterol       Date:  2021-05-07       Impact factor: 5.742

8.  Association of Pretransplant Renal Function With Liver Graft and Patient Survival After Liver Transplantation in Patients With Nonalcoholic Steatohepatitis.

Authors:  Miklos Z Molnar; Kiran Joglekar; Yu Jiang; George Cholankeril; Mubeen Khan Mohammed Abdul; Satish Kedia; Humberto C Gonzalez; Aijaz Ahmed; Ashwani Singal; Kalyan Ram Bhamidimarri; Guruprasad Padur Aithal; Ajay Duseja; Vincent Wai-Sun Wong; Agayeva Gulnare; Puneet Puri; Satheesh Nair; James D Eason; Sanjaya K Satapathy
Journal:  Liver Transpl       Date:  2019-03       Impact factor: 5.799

9.  Estimation of the Prevalence of Nonalcoholic Fatty Liver Disease in an Adult Population in Northern China Using the Data Mining Approach.

Authors:  TengFei Yang; Bo Zhao; Dongmei Pei
Journal:  Diabetes Metab Syndr Obes       Date:  2021-07-28       Impact factor: 3.168

10.  Sub-chronic microcystin-LR renal toxicity in rats fed a high fat/high cholesterol diet.

Authors:  Tarana Arman; Katherine D Lynch; Michael Goedken; John D Clarke
Journal:  Chemosphere       Date:  2020-10-27       Impact factor: 7.086

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.